Curated News
By: NewsRamp Editorial Staff
November 10, 2026
NanoViricides Advances NV-387 Toward Phase II Trials for Measles
TLDR
- NanoViricides advances NV-387 to Phase II for measles, potentially gaining Priority Review Voucher and first-mover advantage in an unmet market.
- NV-387, a broad-spectrum antiviral, completed Phase I safety and juvenile toxicity studies, and is now being prepared for Phase II measles trials via FDA IND process.
- NanoViricides' NV-387 could provide a new treatment for measles, addressing rising cases and improving global health outcomes for children.
- NV-387 is being tested for measles, Ebola, and mpox, showing promise as a broad-spectrum antiviral with Orphan Drug and Rare Pediatric Disease designations.
Impact - Why it Matters
The push toward Phase II trials for NV-387 comes at a critical time, as measles cases are rising in the U.S. and globally, underscoring the urgent need for new antiviral treatments. If successful, NV-387 could become a first-of-its-kind broad-spectrum antiviral that addresses not only measles but also other serious viral diseases like Ebola and mpox. The FDA’s Orphan Drug and Rare Pediatric Disease designations highlight the potential of this therapy to fill a significant gap in pediatric care, and the possibility of a Priority Review Voucher could accelerate its availability. For investors, this milestone signals progress in NanoViricides’ pipeline and validates its nanoviricide platform, while for public health, it offers hope against a resurgent and highly contagious virus.
Summary
NanoViricides, Inc. (NYSE American: NNVC) is advancing its investigational broad-spectrum antiviral drug NV-387 toward Phase II clinical trials for the treatment of measles. The company is developing a clinical trial protocol for submission to the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) process. NV-387 has demonstrated antiviral activity against measles in a humanized mouse model and completed a juvenile mouse toxicity study in which no treatment-related adverse effects were observed at the highest dose tested. The drug has also completed a Phase I human safety study and is currently being evaluated in separate Phase II trials for Ebola Bundibugyo virus and mpox in the Democratic Republic of Congo.
NV-387 has received both Orphan Drug Designation and Rare Pediatric Disease Drug (RPDD) Designation from the FDA for measles treatment. The RPDD designation could make NanoViricides eligible for a Priority Review Voucher following approval of a qualifying marketing application, subject to applicable requirements. The company said the development program addresses an unmet medical need amid rising measles cases in the United States and internationally. NV-387 remains investigational and has not been approved for treating measles or any other viral disease. To view the full press release, visit https://ibn.fm/lWeDl.
NanoViricides, Inc. (www.nanoviricides.com) is a clinical stage company creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(TM) class of drug candidates and technology are based on intellectual property from TheraCour Pharma, Inc. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Another advanced candidate is NV-HHV-1 for shingles. The company is also developing drugs against a range of viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. For the latest news and updates relating to NNVC, visit the company’s newsroom at https://ibn.fm/NNVC.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances NV-387 Toward Phase II Trials for Measles
